New approach to cancer therapy: Heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule

Anticancer Research

Volumn 27, Issue 6 A, 2007, Pages 3713-3721

  Miyamoto, Shingo ^a   Yagi, Hiroshi ^b   Yotsumoto, Fusanori ^a   Horiuchi, Shinji ^a   Yoshizato, Toshiyuki ^a   Kawarabayashi, Tatsuhiko ^a   Kuroki, Masahide ^a   Mekada, Eisuke ^c  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

HB EGF; Ovarian cancer; Review; Target; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CROSS REACTING MATERIAL 197; CROSSREACTING MATERIAL 197; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CROSS REACTION; DRUG INHIBITION; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE IRRITATION; NONHUMAN; OVARY CANCER; PERITONEAL FLUID; PHENOTYPE; PRIORITY JOURNAL; SKIN IRRITATION; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL PROTEINS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FORECASTING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 35348993675     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48, 1998.
2. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
3. Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506-1507, 2004.
4. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J and Aaronson SA: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070, 1987.
5. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
6. Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21, 2003.
7. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2449, 2005.
8. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
9. Athale CA and Deisboeck TS: The effects of EGF-receptor density on multiscale tumor growth patterns. J Theor Biol 238: 771-779, 2006.
10. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting EGFR signaling in cancer: from expression and turnover. Biochem Biophys Acta 1766: 120-139, 2006.
11. El-Obeid A, Hesselager G, Westermark B and Nister M: TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor. Biochem Biophys Res Commun 290: 349-358, 2002.
12. Sporn MB and Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878-880, 1980.
13. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H and Nexo E: A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 61: 6227-6233, 2001.
14. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H and Mekada E: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727, 2004.
15. Higashiyama S, Abraham JA, Miller J, Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991.
16. Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30, 2003.
17. Fischer OM, Hart S, Gschwind A and Ullrich A: EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203-1208, 2003.
18. Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, Yamazaki A, Kimura R, Mizushima H, Moribe H, Higashiyama S, Endoh M, Kaneda Y, Takagi S, Itami S, Takeda N, Yamada G and Mekada E: Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 163: 469-475, 2003.
19. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M and Mekada E: Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which upregulates functional receptors and diphtheria toxin sensitivity. EMBO J 13: 2322-2330, 1994.
20. Nakamura K, Iwamoto R and Mekada E: Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at cell-cell contact sites. J Cell Biol 129: 1691-1705, 1995.
21. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M and Mekada E: The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 128: 929-938, 1995.
22. Nanba D, Mammoto A, Hashimoto K and Higashiyama S: Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502, 2003.
23. Lin J, Hutchinson L, Gaston SM, Raab G and Freeman MR: BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 276: 30127-30132, 2001.
24. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA and Reed JC: Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80: 279-284, 1995.
25. Krug U, Ganser A and Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21: 3475-3495, 2002.
26. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C and Lee DC: Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 22: 2704-2716, 2003.
27. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M and Mekada E: Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 100: 3221-3226, 2003.
28. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A and Lee DC: Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750, 1999.
29. Raab G and Klagsbrun M: Heparin-binding EGF-like growth factor. Biochimica Biophysica Acta 1333: F179-199, 1997.
30. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T and Mekada E: Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 97: 341-347, 2006.
31. Mills GB, May C, McGill M, Roifman CM and Mellers A: A putative new growth factor in ascetic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48: 1066-1071, 1988.
32. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E and Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Brit J Cancer 92: 1737-1745, 2005.
33. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E and Nakano H: Clinical significance of heparin-binding EGF (epidermal growth factor)-like growth factor and ADAM (a disintegrin and metalloprotease) 17 expression in human ovarian cancer. Clin Cancer Res 11: 4783-4792, 2005.
34. Sarosy G and Reed E: Taxol dose intensification and its clinical implications. J Natl Med Assoc 85: 427-431, 1993.
35. Rowinsky EK: Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 28: S18-22, 1994.
36. Mitamura T, Higashiyama S, Taniguchi N, Klgasbrun M and Mekada E: Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270: 1015-1019, 1995.
37. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C and Pironi F: CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 53: 1041-1048, 2004.
38. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P and Korc M: Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202: 1705-1709, 1994.
39. Naef M, Yokoyama M, Friess H, Buchler MW and Korc M: Coexpression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 66: 315-321, 1996.
40. Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M, Monden M and Matsuura N: Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncology Reports 8: 903-907, 2001.
41. Ito Y, Higashiyama S, Takeda T, Yamamoto Y, Wakasa KI and Matsuura N: Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int J Pancreatol 29: 47-52, 2001.
42. Suganuma K, Kubota T, Saikawa Y, Abe S, Otani Y, Furukawa T, Kumai K, Hasegawa H, Watanabe M, Kitajima M, Nakayama H and Okabe H: Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 94: 355-359, 2003.
43. Wang F, Liu R, Lee SW, Sloss CM, Couget J and Cusack JC: Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016, 2007.
44. Morgillo F and Lee HY: Resistance to epidermal growth factor receptor-targeted therapy. Drug Resistance Updates 8: 298-310, 2005.
45. Wong AJ, Ruppert JM, Binger SH, Grzeschik CH, Humphrey PA, Bigner DS and Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965-2969, 1992.
46. Ramnarain DB, Park S, Lee DY, Hatnpaa KJ, Scoggin SO, Out H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R and Habib AA: Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66: 867-874, 2006.
47. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
48. Settleman J: Inhibition of mutant EGF receptors by gefitinib: targeting an achilles' heel of lung cancer. Cell Cycle 3: 1496-1497, 2004.
49. Friday BB and Adjei AA: K-ras as a target for cancer therapy. Biochem Biophys Acta 1756: 127-144, 2005.
50. Gangarosa M, Sizemore N, Graves-Deal R, Oldham SM, Der CJ and Coffey RJ: A raf-independent epidermal growth factor receptor autocrine loop is necessary for ras transformation of rat intestinal epithelial cells. J Biol Chem 272: 18926-18931, 1997.
51. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yagen Y: A hierarchial network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
52. Normanno N, Selvam MP, Qi C, Saeki T, Johnson GR, Kim N, Ciardiello F, Shoyab M, Plowman GD, Todaro GJ and Salmon DS: Amphiregulin as an autocrine growth factor for c-Ha-ras-and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci USA 91: 2790-2794, 1994.
53. Lu Y, Zi X, Zhao Y, Mascarrenhas D and Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857, 2001.
54. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and Nicholson RI: Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839); Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814, 2004.
55. Roudabush FL, Pierce KL, Maudsley S, Khan KD and Luttrell LM: Transactivation of the EGF receptor mediates IGF-I-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 275: 22583-22589, 2000.